非感染性葡萄膜炎治疗退出选择登记研究:3年时参与者特征
TOFU登记研究为观察性前瞻性登记,纳入德国和奥地利25个临床中心的628例非前部非感染性葡萄膜炎患者。基线时39.6%使用全身糖皮质激素,22.3%使用传统合成DMARD,20.5%使用生物DMARD;平均最佳矫正视力为0.69小数,仅8例(1.3%)存在严重视力损害。
要点
- 基线时不足半数参与者需要DMARD治疗,传统合成DMARD使用频率高于生物DMARD。
- 严重视力损害发生率低(1.3%),主要见于全葡萄膜炎患者。
- 中间型葡萄膜炎最常见(40.1%),其次为后部葡萄膜炎(28.8%)和全葡萄膜炎(24.5%)。
核心结论
- 基线时不足半数参与者需要DMARD治疗,传统合成DMARD使用频率高于生物DMARD。
- 严重视力损害发生率低,主要影响全葡萄膜炎患者。
- 这些发现与德国三级葡萄膜炎中心的可比单中心横断面研究一致,将有助于在TOFU中产生可推广的证据。
研究设计与样本
- TOFU为观察性前瞻性登记研究,招募≥18岁有或无既往改善病情抗风湿药(DMARD)治疗史的非前部非感染性葡萄膜炎患者。
- 2019年10月24日至2022年12月27日期间,在德国和奥地利的25个临床中心共纳入628例患者。
- 数据通过电子数据采集软件REDCap收集,包括眼科和一般病史以及临床发现。
主要发现
- 中间型葡萄膜炎最常见(n=252;40.1%),其次为后部葡萄膜炎(181;28.8%)、全葡萄膜炎(n=154;24.5%)和视网膜血管炎(n=41;6.5%)。
- 基线时39.6%接受全身糖皮质激素治疗,22.3%接受传统合成(cs)DMARD,20.5%接受生物(b)DMARD,3.6%接受其他全身治疗。
- 平均最佳矫正视力(BCVA)为0.69小数;全葡萄膜炎患者BCVA最差,为0.63小数。
- 总体仅8例患者(1.3%)存在严重视力损害。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The Treatment exit Options For non-infectious Uveitis (TOFU) registry documents disease courses for non-anterior non-infectious uveitis entities with and without treatment to generate more evidence for clinical management recommendations including treatment exit strategies. In this article, we present the participants' baseline characteristics after the first 3 years. METHODS: TOFU is an observational, prospective registry and recruits patients ≥18 years of age with non-anterior non-infectious uveitis with or without a history of previous disease-modifying antirheumatic drugs (DMARDs) treatment. The data are collected in the electronic data capture software REDCap and include ophthalmological and general medical history as well as clinical findings. RESULTS: Between 24.10.2019 and 27.12.2022, 628 patients were enrolled at 25 clinical sites in Germany and Austria. Patients with intermediate uveitis were most frequently included (n=252; 40.1%) followed by posterior uveitis (181; 28.8%), panuveitis (n=154; 24.5%) and retinal vasculitis (n=41, 6.5%). At baseline, 39.6% were treated with systemic corticosteroids, 22.3% with conventional synthetic (cs) DMARDs, 20.5% with biological (b) DMARDs and 3.6% with other systemic treatments. Average best corrected visual acuity (BCVA) was 0.69 decimal. Patients with panuveitis had the worst BCVA with 0.63 decimal. Overall, only 8 patients (1.3%) suffered from severe visual impairment. CONCLUSIONS: Less than half of participants required DMARD treatment at baseline, with csDMARDs used more frequently than bDMARDs. The presence of severe visual impairment was low, mostly affecting patients with panuveitis. These findings are in line with comparable monocentric cross-sectional studies of tertiary uveitis centres in Germany and will allow us to generate generalisable evidence in TOFU.
引用
- Fink DJ, Dell J, Heinz C, et al. Treatment exit options for non-infectious uveitis registry: participant characteristics at 3 years. Br J Ophthalmol. 2024. PMID: 38857972. doi:10.1136/bjo-2023-324927
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。